事后分析显示,在接受大量造影剂的PCI亚组患者中,与安慰剂组相比,rhC1INH组的尿NGAL中位绝对峰值和相对峰值明显小于安慰剂组(1.8 ng/ml[IQR:-2.7-12.5] vs.26.2 ng/ml[IQR:16.0-133.8];P=0.039;11%[IQR:-5%-74%] vs.205%[IQR:84%-469%];P=0.002),而在非PCI患者中无明显差异。 次要终点方面,RhC1...
rhC1INH: a new drug for the treatment of attacks in he- reditary angioedema caused by C1-inhibitor deficiency. Exp Rev Clin Immunol. 2011;7:143e153.Varga L, Farkas H. RhC1INH: A new drug for the treatment of attacks in hereditary angioedema caused by C1‑inhibitor deficiency....
摘要: 目的:分析重组人C1酯酶抑制剂(rhC1INH)中相关蛋白rcc-rhC1INH和ox-rhC1INH的含量.方法:采用反相高效液相色谱法进行测定,对该方法进行专属性、准确性和精密度检验,并用该方法对4批样品中的相关蛋白进行检测.结果:低浓度下,rhC1INH对照品、rcc-rhC1INH对照品和ox-rhC1INH对照品能够较好分离.rcc-rhC1INH...
rhC1INH: a new drug for the treatment of attacks in he- reditary angioedema caused by C1-inhibitor deficiency. Exp Rev Clin Immunol. 2011;7:143e153.Varga L, Farkas H. rhC1INH: a new drug for the treatment of attacks in hereditary angioedema caused by C1-inhibitor deficiency. Expert...
rhC1INH Cuts Attack Frequency in Hereditary AngioedemaNewsJaapa
Clinical studies of recombinant human Cl inhibitor (rhC1-INH) in patients with acute attacks of hereditary angioedema [abstract]. J Allergy Clin Immunol 2008; 121(3): 797Nuijens J, Verdotik R, Gianneti C, et al. Clinical studies of recombinant human C1 inhibitor (rhC1INH) in ...
Recombinant Human C1 Inhibitor (rHC1INH) Is Efficacious and Well Tolerated As Prophylaxis for Prevention of Hereditary Angioedema (HAE) Attacks: A Randomized, Phase 2 TrialAim: To determine the frequency of diabetic ketoacidosis in diabetic patients presenting in a tertiary care setting and frequency...
Bodyweight (population weight, 16-128 kg) was a key predictor of C1-INH volume of distribution. Age was not a predictor of C1-INH PK after inclusion of bodyweight in the model. Simulations of the recommended rhC1-INH dosing regimen (bodyweight <84 kg, 50 U/kg; ≥84 kg, 4200 U) ...
rhC1inh was well tolerated (no allergic reactions) and showed the desired biological activity (C4 increases and inhibition of C4b/c formation) and will be tested in phase II studies in patients with severe attacks of angioedema. Clinical Pharmacology & Therapeutics (2004) 75 , P52鈥揚52; doi...
rhC1inh was well tolerated (no allergic reactions) and showed the desired biological activity (C4 increases and inhibition of C4b/c formation) and will be tested in phase II studies in patients with severe attacks of angioedema. Clinical Pharmacology & Therapeutics (2004) 75 , P52鈥揚52; doi...